ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.

Airiau, Kelly

ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. [electronic resource] - Experimental hematology May 2012 - 367-78.e2 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1873-2399

10.1016/j.exphem.2012.01.004 doi


Antigens, CD34--analysis
Antineoplastic Agents--pharmacology
Apoptosis--drug effects
Apoptosis Regulatory Proteins--physiology
Bcl-2-Like Protein 11
Benzamides
Biphenyl Compounds--pharmacology
Cell Line, Tumor--drug effects
Down-Regulation--drug effects
Drug Resistance, Neoplasm--drug effects
Drug Screening Assays, Antitumor
Drug Synergism
Gene Expression Regulation, Leukemic--drug effects
Hematopoietic Stem Cells--drug effects
High-Temperature Requirement A Serine Peptidase 2
Humans
Imatinib Mesylate
K562 Cells--drug effects
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--pathology
Membrane Proteins--physiology
Mitochondrial Proteins--physiology
Neoplasm Proteins--biosynthesis
Neoplastic Stem Cells--drug effects
Nitrophenols--pharmacology
Piperazines--pharmacology
Protein Kinase Inhibitors--pharmacology
Proto-Oncogene Proteins--physiology
Proto-Oncogene Proteins c-bcl-2--antagonists & inhibitors
Pyrimidines--pharmacology
Serine Endopeptidases--physiology
Sulfonamides--pharmacology
X-Linked Inhibitor of Apoptosis Protein--biosynthesis